Recent advances in retrometabolic drug design (RMDD) and development

Pharmazie

Volumn 65, Issue 6, 2010, Pages 395-403

  Bodor, Nicholas ^a   Buchwald, P ^b,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ATI 2042; BREVIBLOCK; BROMAZEPAM; CISAPRIDE; CYCLOSPORIN; CYTOKINE; DIHYDROQUINOLINE DERIVATIVE; ESMOLOL; ETOMIDATE; FLUTICASONE PROPIONATE; LANDIOLOL; METOPROLOL; MIDAZOLAM; MOMETASONE FUROATE; REMIFENTANIL; RITALINIC ACID; TACROLIMUS; UNCLASSIFIED DRUG;

ANESTHESIOLOGY; ASTHMA; AUTOIMMUNE DISEASE; CRITICALLY ILL PATIENT; DRUG DESIGN; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG SAFETY; HEART ATRIUM FIBRILLATION; LIPOPHILICITY; METABOLITE; PHARMACOPHORE; REVIEW; STOMACH PARESIS; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; HUMAN; METABOLOMICS;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; METABOLOMICS;

EID: 77955296167     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2010.0523R     Document Type: Review

References (64)

1. Arya A, Silberbauer J, Teichman SL, Milner P, Sulke N, Camm AJ (2009) A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Europace 11: 458-464.
2. Bodor N (1977) Novel approaches for the design of membrane transport properties of drugs. In: Roche EB (ed), Design of Biopharmaceutical Properties through Prodrugs and Analogs. Washington, D.C.: Academy of Pharmaceutical Sciences, pp. 98-135.
3. Bodor N (1982) Designing safer drugs based on the soft drug approach. Trends Pharmacol Sci 3: 53-56.
4. Bodor N (1984) Soft drugs: principles and methods for the design of safe drugs. Med Res Rev 3: 449-469.
5. Bodor N (1997) Redox amino acids and peptides containing them. US Patent 5,639,885.
6. Bodor N (1999) Androstene derivatives. U.S. Patent 5,981,517.
7. Bodor N, Brewster ME (1991) Chemical delivery systems. In: Juliano RL (ed), Targeted Drug Delivery, Vol 100. Berlin: Springer, pp. 231-284.
8. Bodor N, Buchwald P (1997a) Drug targeting via retrometabolic approaches. Pharmacol Ther 76: 1-27. (Pubitemid 28078557)
9. Bodor N, Buchwald P (1997b) Molecular size based approach to estimate partition properties for organic solutes. J Phys Chem B 101: 3404-3412. (Pubitemid 127627825)
10. Bodor N, Buchwald P (1999) Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv Drug Deliv Rev 36: 229-254. (Pubitemid 29121974)
11. Bodor N, Buchwald P (2000) Soft drug design: general principles and recent applications. Med Res Rev 20: 58-101. (Pubitemid 30027561)
12. Bodor N, Buchwald P (2003a) Brain-targeted delivery: experiences to date. Am J Drug Deliv 1: 13-26.
13. Bodor N, Buchwald P (2003b) Retrometabolism-based drug design and targeting. In: Abraham DJ (ed), Burger's Medicinal Chemistry and Drug Discovery. Vol. 2, Drug Discovery and Drug Development, 6th Edition, New York: Wiley, pp. 533-608.
14. Bodor N, Buchwald P (2005) Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J. 7: article 79 (E820-E833).
15. Bodor N, Buchwald P (2006a) Brain-targeted delivery of estradiol: therapeutic potential and results obtained with a chemical delivery system approach. Am J Drug Deliv 4: 161-175. (Pubitemid 44338315)
16. Bodor N, Buchwald P (2006b) Brain-targeted delivery of peptides. Am Pharm Rev 9: 100-104.
17. Bodor N, Buchwald P (2006c) Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids. Curr Pharm Des 12: 3241-3260. (Pubitemid 44375467)
18. Bodor N, Buchwald P, Huang M-J (1998a) Computer-aided soft drug design. Computer software, Copyright University of Florida. Gainesville, FL.
19. Bodor N, Buchwald P, Huang M-J (1998b) Computer-assisted design of new drugs based on retrometabolic concepts. SAR QSAR Environ Res 8: 41-92.
20. Bodor N, Buchwald P, Huang M-J (1999) The role of computational techniques in retrometabolic drug design strategies. In: Leszczynski J (ed), Computational Molecular Biology. Amsterdam: Elsevier, pp. 569-618.
21. Bodor N, Farag HH, Barros MDC, Wu W-M, Buchwald P (2002) In vitro and in vivo evaluations of dihydroquinoline- and dihydroisoquinoline-based targetor moieties for brain-specific chemical delivery systems. J Drug Targeting 10: 63-71.
22. Bodor N, Gabanyi Z, Wong C-K (1989) A new method for the estimation of partition coefficient. J Am Chem Soc 111: 3783-3786.
23. Bodor N, Prokai L, Wu W-M, et al (1992) A strategy for delivering peptides into the central nervous system by sequential metabolism. Science 257: 1698-1700.
24. Bodor N, Shek E, Higuchi T (1975) Delivery of a quaternary pyridinium salt across the blood-brain barrier by its dihydropyridine derivative. Science 190: 155-156.
25. Buchwald P (2005) General linearized biexponential model for QSAR data showing bilinear-type distribution. J Pharm Sci 94: 2355-2379.
26. Buchwald P (2007a) Computer-aided retrometabolic drug design: soft drugs. Expert Opin Drug Discov 2: 923-933.
27. Buchwald P (2007b) A general bilinear model to describe growth or decline time-profiles. Math Biosci 205: 108-136.
28. Buchwald P (2008) Glucocorticoid receptor binding: a biphasic dependence on molecular size as revealed by the bilinear LinBiExp model. Steroids 73: 193-208.
29. Buchwald P, Bodor N (1998) Octanol-water partition of nonzwitterionic peptides: Predictive power of a molecular size-based model. Proteins 30: 86-99. (Pubitemid 28036113)
30. Buchwald P, Bodor N (2002) Computer-aided drug design: the role of quantitative structure-property, structure-activity, and structure-metabolism relationships (QSPR, QSAR, QSMR). Drugs Future 27: 577-588.
31. Buchwald P, Bodor N (2004) Soft glucocorticoid design: structural elements and physicochemical parameters determining receptor-binding affinity. Pharmazie 59: 396-404. (Pubitemid 38720350)
32. Buchwald P, Bodor N (2006) Soft quaternary anticholinergics: comprehensive QSAR with a linearized biexponential (LinBiExp) model. J Med Chem 49: 883-891.
33. 4 receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 19: 30-38.
34. Chen P, Bodor N, Wu W-M, Prokai L (1998) Strategies to target kyotorphin analogues to the brain. J Med Chem 41: 3773-3781. (Pubitemid 28447304)
35. Cotten JF, Husain SS, Forman SA, et al (2009) Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression. Anesthesiology 111: 240-249.
36. Egan TD (2009) Is anesthesiology going soft? Trends in fragile pharmacology. Anesthesiology 111: 229-230.
37. Foucout L, Gourand F, Dhilly M, et al (2009) Synthesis, radiosynthesis and biological evaluation of 1,4-dihydroquinoline derivatives as new carriers for specific brain delivery. Org. Biomol Chem 7: 3666-3673.
38. Freyne EJ, Lacrampe JF, Deroose F, et al (2005) Synthesis and biological evaluation of 1,2,4-triazinylphenylalkylthiazolecarboxylic acid esters as cytokine-inhibiting antedrugs with strong bronchodilating effects in an animal model of asthma. J Med Chem 48: 2167-2175. (Pubitemid 40396344)
39. Hassan HA, Abdel-Aziz M, Abuo-Rahma Gel D, Farag HH (2009) 1-Malonyl-1,4-dihydropyridine as a novel carrier for specific delivery of drugs to the brain. Bioorg Med Chem 17: 1681-1692.
40. Hersperger R, Buchheit K-H, Cammisuli S, et al (2004) A locally active antiinflammatory macrolide (MLD987) for inhalation therapy of asthma. J Med Chem 47: 4950-4957. (Pubitemid 39238270)
41. Holland EJ, Djalilian AR, Sanderson JP (2009) Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation. Cornea 28: 1139-1143.
42. Howes JF (2000) Loteprednol etabonate: a review of ophthalmic clinical studies. Pharmazie 55: 178-183. (Pubitemid 30208211)
43. Ilyas H, Slonim CB, Braswell GR, Favetta JR, Schulman M (2004) Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens 30: 10-13. (Pubitemid 43196972)
44. Kilpatrick GJ, McIntyre MS, Cox RF, et al (2007) CNS 7056: a novel ultra-short-acting benzodiazepine. Anesthesiology 107: 60-66.
45. Kilpatrick GJ, Tilbrook GS (2006) Drug development in anaesthesia: industrial perspective. Curr Opin Anaesthesiol 19: 385-389. (Pubitemid 44048259)
46. Kumar GN, Bodor N (1996) Soft anticholinergics. Curr Med Chem 3: 23-36.
47. Labaree DC, Reynolds TY, Hochberg RB (2001) Estradiol-16α- carboxylic acid esters as locally active estrogens. J Med Chem 44: 1802-1814.
48. Labaree DC, Zhang JX, Harris HA, O'Connor C, Reynolds TY, Hochberg RB (2003) Synthesis and evaluation of B-, C-, and D-ring-substituted estradiol carboxylic acid esters as locally active estrogens. J Med Chem 46: 1886-1904. (Pubitemid 36532232)
49. Lazarova T, Chen JS, Hamann B, et al (2003) Synthesis and biological evaluation of novel cyclosporin A analogues: potential soft drugs for the treatment of autoimmune diseases. J Med Chem 46: 674-676. (Pubitemid 36258857)
50. Markowitz JS, DeVane CL, Boulton DW, et al (2000) Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol. Drug Metab Dispos 28: 620-624.
51. Morey TE, Seubert CN, Raatikainen MJP, et al (2001) Structure-activity relationships and electrophysiological effects of short-acting amiodarone homologs in guinea pig isolated heart. J Pharmacol Exp Ther 297: 260-266.
52. Noble S, Goa KL (1998) Loteprednol etabonate. Clinical potential in the management of ocular inflammation BioDrugs 10: 329-339.
53. Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5: 993-996.
54. Pacofsky GJ, Stafford JA, Cox RF, et al (2002) Relating the structure, activity, and physical properties of ultrashort-acting benzodiazepine receptor agonists. Bioorg Med Chem Lett 12: 3219-3222.
55. Patrick KS, Kilts CD, Breese GR (1981) Synthesis and pharmacology of hydroxylated metabolites of methylphenidate. J Med Chem 24: 1237-1240.
56. Prokai-Tatrai K, Kim HS, Prokai L (2008) The utility of oligopeptidase in brain-targeting delivery of an enkephalin analogue by prodrug design. Open Med Chem J 2: 97-100.
57. Prokai-Tatrai K, Perjési P, Zharikova AD, Li X, Prokai L (2002) Design, synthesis, and biological evaluation of novel, centrally-acting thyrotropin-releasing hormone analogues. Bioorg Med Chem Lett 12: 2171-2174.
58. Prokai-Tatrai K, Prokai L (2009) Prodrugs of thyrotropin-releasing hormone and related peptides as central nervous system agents. Molecules 14: 633-654.
59. Prokai L, Prokai-Tatrai K, Zharikova AD, Nguyen V, Perjesi P, Stevens SM, Jr. (2004) Centrally acting and metabolically stable thyrotropin-releasing hormone analogues by replacement of histidine with substituted pyridinium. J Med Chem 47: 6025-6033.
60. Proudfoot JR (2002) Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. Bioorg Med Chem Lett 12: 1647-1650.
61. Raatikainen MJP, Morey TE, Druzgala P, Milner P, Gonzalez MD, Dennis DM (2000) Potent and reversible effects of ATI-2001 on atrial and atrioventricular nodal electrophysiological properties in guinea pig isolated perfused heart. J Pharmacol Exp Ther 295: 779-785.
62. Sandham DA, Barker L, Beattie D, et al (2004) Synthesis and biological properties of novel glucocorticoid androstene C-17 furoate esters. Bioorg Med Chem 12: 5213-5224.
63. Stafford JA, Pacofsky GJ, Cox RF, et al (2002) Identification and structure-activity studies of novel ultrashort-acting benzodiazepine receptor agonists. Bioorg Med Chem Lett 12: 3215-3218.
64. 2]-TRH. J Pharm Pharmacol 54: 945-950.